Qianqian Zhao

Qianqian Zhao

Auto-generated profile, based on publicly available information

Qianqian Zhao

Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2025 in Chemical Engineering Journal
Verified
Journal Article
Closed access
HWHaoyang Wu
Haoyang Wu
QZQianqian Zhao
Qianqian Zhao
SJShan Jiang
Shan Jiang
WLWei Liu
Wei Liu
HXHuining Xiao
Huining Xiao
WWWeibing Wu
Weibing Wu

1 January 2022 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
QZQianqian Zhao
Qianqian Zhao
TLTingting Li
Tingting Li
SDShisuo Du
Shisuo Du
JHJian He
Jian He
ZZZhaochong Zheng
Zhaochong Zheng
Background: To evaluate the potential impact of radiation time on radiation-induced lymphopenia (RIL) and subsequently recovery after stereotactic body radiation therapy (SBRT) and to examine the associations between radiation time and with patient outcomes in early-stage non-small cell lung cancer (NSCLC). Methods: Clinical and laboratory records of subjects consisted of 115 patients who had received SBRT for early-stage NSCLC. Clinical and laboratory records were retrospective reviewed to assess the changes in total lymphocyte counts (TLCs) following SBRT. Associations of TLCs kinetics with the clinical and treatment features, and outcomes were analyzed. Results: Most patients (100/115, 86.96%) experienced significantly decreased median TLCs following SBRT (1700 vs 1100 cells/µL; P < .001), and 52 patients (45.21%) met the criteria for lymphopenia. Six months after SBRT, 44 patients (38.26%) had recovered. A negative correlation between TLCs reduction and radiation time was observed ( r = −0.381, P < .001). According to the receiver-operating characteristic curve analysis, the optimal cut-off value for radiation time to was 3950 s to predict lymphocyte count recovery (LR) following RIL was 3950 s ( P < .001). Multivariate analyses demonstrated that radiation time was significantly associated with LR (odds ratio [OR], 0.113; 95% confidence interval [CI], 0.029-0.432; P = .001) but not TLCs reduction ( P = .575). LR within 6 months after SBRT was associated with improved progression-free survival in patients without non-lymphopenia ( P = .034), but had little effect in patients with lymphopenia ( P = .405). Conclusion: A longer radiation time was associated with a lower rate of LR within 6 months after SBRT in patients with early-stage NSCLC. Given the association of severe and persistent RIL with survival in NSCLC, further study of the effect of radiation time on immune status is warranted.

1 November 2018 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
QZQianqian Zhao
Qianqian Zhao
GCGang Chen
Gang Chen
LYLuxi Ye
Luxi Ye
ZZZhaochong Zeng
Zhaochong Zeng
SSShiming Shi
Shiming Shi
JHJian He
Jian He
Purpose: Following surgery for early stage non-small-cell lung cancer (NSCLC), de novo pulmonary tumors are common. This study aimed to assess the efficacy, patterns of failure, and toxicity of stereotactic body radiotherapy (SBRT) in the treatment of de novo pulmonary tumors following curative resection of early stage NSCLC. Patients and methods: We reviewed the medical data of patients who had received definitive intent SBRT for small lung cancer at Zhongshan Hospital, Fudan University, between June 2011 and December 2017. Patients who had experienced complete resection for prior early stage NSCLC before SBRT were identified for further analysis. Incidences of locoregional recurrence (LR) and distant metastasis (DM) were evaluated using the alternative cumulative incidence competing risk method. The probability of survival was estimated using the Kaplan–Meier method. Results: A total of 33 patients with 36 lesions were eligible and included in this study. The median follow-up time was 32 months. Estimated incidences of LR and DM were 37.62% and 15.92%, respectively, at 1 year and 48.02% and 21.23%, respectively, at 2 years. The progression-free survival and overall survival of all patients were 62.40% and 90.30%, respectively, at 1 year and 52.00% and 69.90%, respectively, at 2 years. In all, 26 patients experienced grade 1 SBRT-related toxicity, 11 patients experienced grade 2 SBRT-related toxicity, and three patients experienced grade 3 toxicity. There were no grade 4/5 toxicities or SBRT-related deaths during the follow-up period. Conclusion: SBRT appears to be a safe and potentially effective alternative therapeutic option for de novo pulmonary tumors following early stage NSCLC radical resection, despite impaired pulmonary reserve.

8 August 2019 in World Chinese Journal of Digestology
Verified
Journal Article
Open access
SCSi-Xu Chen
Si-Xu Chen
ZSZhan-Min Shang
Zhan-Min Shang
JHJianyu Hao
Jianyu Hao
QZQian-Qian Zhao
Qian-Qian Zhao
XSXiao Sun
Xiao Sun
YWYu-Na Wei
Yu-Na Wei